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Abstract
Background:  MAdCAM-1 is an adhesion molecule expressed in Peyer's patches and lymphoid
tissues which is mobilized by cytokines like TNF-α  and is a major determinant of lymphocyte
trafficking to the gut in human inflammatory bowel disease (IBD). It has been suggested that both
reactive oxygen and nitrogen metabolites participate in regulating adhesion molecule expression in
response to TNF-α .
Methods:  To examine how exogenous and endogenous sources of NO modulate MAdCAM-1
induction by TNF-α , we pre-treated mouse lymphatic endothelial cells with either long or short
acting NO donors prior to TNF-α -stimulation, and measured MAdCAM-1 induction at 24 h.
Results and Discussion:  DETA-NO, a long-acting NO donor, and SperNO, a rapid releasing
NO donor both inhibited TNF-α -stimulated MAdCAM-1 expression in a concentration dependent
manner. Both NO donors also reduced a4b7-dependent lymphocyte endothelial adhesion.
Inhibition of endogenous NO production by either L-NAME, a non-selective NOS inhibitor, or by
1400 w, a selective iNOS inhibitor failed to induce, or potentiate TNF-α  regulated MAdCAM-1
expression.
Conclusions:   Exogenous NO donors may be beneficial in the treatment of IBD, while
endogenous nitric oxide synthases may be less effective in controlling adhesion molecule
expression in response to cytokines.
Background & Aims
MAdCAM-1 is a 60 kD endothelial cell adhesion mole-
cule expressed on the surface of high endothelial venules
in the gut, and in Peyers patches. MAdCAM-1 is ex-
pressed basally in these tissues and is dramatically in-
creased in inflammatory bowel disease (IBD). In IBD,
especially Crohn's disease, MAdCAM-1 acts as the main
ligand for a4b7-expressing lymphocytes and recruits
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these lymphocytes into the intestine where they initiate
and sustain chronic inflammation. Several animal mod-
els and human studies support an absolute requirement
for both MAdCAM-1 and a4b7 in the production of im-
mune models of colitis. MAdCAM-1 is expressed on the
surface of lymphoid endothelial cells in response to sev-
eral cytokines including TNF-α  and IL-lb, however, the
signal transduction pathways involved in MAdCAM-1
are still not well understood. However, since MAdCAM-
1 is induced by Th1 cytokines, like TNF-α  and IL-1b, it is
likely that its induction is mechanistically similar to that
of adhesion molecules like ICAM-1 and VCAM-1. These
adhesion molecules are also induced by Th1 cytokines
and require activation of the NF-kB/PARP. The activa-
tion of these transcription factors also requires the for-
mation of intracellular oxidants, since mobilization of
these adhesion molecules in response to cytokines can be
prevented by antioxidants like PDTC or NAC. Physiolog-
ically, the expression of these cell adhesion molecules
also appears to be limited by the formation of NO
through either constituitive, or inducible forms of nitric
oxide synthase (eNOS, iNOS). It has been suggested that
NO could inhibit the transcription/translation of adhe-
sion molecules through either scavenging of signal oxi-
dants produced in response to cytokines, or through
covalent modification of polypeptides in the signaling
pathway, like IkB.
Here, we examine the induction of MAdCAM-1 by TNF-
α , and evaluated whether endogenous nitric oxide (from
eNOS and iNOS), or exogenous NO (from rapid or slow-
releasing NO donors) affect the expression of MadCAM-
1. Our data suggest that in this model, endogenous NO
(derived from either iNOS or eNOS), does not signifi-
cantly influence MAdCAM-1 expression, however, both
rapid and slow releasing NO donors can potently inhibit
the expression of MAdCAM-1 and reduce lymphocyte en-
dothelial adhesion.
Materials and Methods
Reagents
Recombinant mouse TNF-α  was purchased from EN-
DOGEN (Stoughton, MA). DETA-NO, SperNO and 1400
w were purchased from Alexis corp. (San Diego, CA). L-
NAME was purchased from Sigma (St. Louis, MO).
Cell culture
SVEC4-10 is an endothelial cell line derived by SV40
(strain 4A) transformation of murine small vascular en-
dothelial cells originally isolated from axillary lymph
node vessels of an adult male C3H/Hej mouse [1]. These
cell types were all maintained in DMEM with 10% fetal
calf serum with 1% antibiotic/ antimycotic, and seeded
onto 24-well tissue culture plates at approximately
20,000 cells/cm2; cultures were used immediately after
reaching confluency.
Lymphocytes
Mouse CD8+ T cell lymphoma TK-1 cells which constitu-
itively express α 4β 7 were obtained from Dr. Eugene
Butcher (Stanford University). These cells were cultured
in RPMI medium supplemented with 10% FCS, 2 mM L-
glutamine, and 0.05 mM 2-mercaptoethanol without an-
tibiotic/antimycotic.
RT-PCR analysis
MAdCAM-1 message in response to TNF-α  and blockers
was measured by RT-PCR. When NO donors were used
they were given as co-treatments, NO synthase blockers
(L-NAME) were pre-treated for 60 minutes prior to incu-
bation. Total cell RNA was extracted from SVEC cells us-
ing the RNeasy Kit (QIAGEN Inc., Valencia, CA)
according to manufacturers instructions. First-strand
cDNAs were prepared from 6 µg of total RNA using a
mixture of oligo(dT)12-18 and random hexamer primers
with Superscript reverse transcriptase (Promega, Madi-
son, WI). The following oligonucleotides were synthe-
sized and used as primers: PI; 5'-
CCTAGTACCCTACCAGCTCA-3' P2; 5'-ATCTCCTCT-
TCTTGCTCTGG-3' (P1-P2; 474 bp)
As controls, a 307 bp (sense; 5'-CGGTGTGAACGGATTT-
GGCCGTAT-3', antisense; 5'-GGCCTTCTCCATGGT-
GGTGAAGAC-3') fragment of murine GAPDH was also
amplified in a same tube with primers 1 and 2. Primer se-
quences for GAPDH were separated by introns to control
for potential sample contamination by genomic DNA.
PCR amplification was performed at 95°C for 3 min; fol-
lowed by 30 cycles of 94°C for 1 min, 55°C for 1 min and
72°C for 1 min, and then at 72°C for the final 5 min. The
PCR products were separated on 1.2% agarose gels. To
normalize mRNA levels, the density of the MAdCAM-1
and GAPDH bands from the same lane were measured
by scanning the three replicate gels (n = 3), using a HP
ScanJet™ flatbed scanner. Images were analyzed for
density using Image Pro Plus™ image analysis software
(Media Cybernetics, Silver Springs, MD). The data are
calculated as the rations of the optical density values to
those of GAPDH, and are presented as a persentage of
TNF-α  stimulated density ration. Significant changes in
MAdCAM-1 densities were determined using the In-
stat™ statistical package (Graphpad Software, San Di-
ego, CA).
Western analysis of cell lysates
Monolayers were pretreated (NO synthase blockers) or
co-treated (NO donors) with cytokines and harvested at
24 hours. Equal quantities of protein (75 µg) from each
sample were electrophoretically separated on 7.5% SDS-BMC Gastroenterology (2001) 1:5 http://www.biomedcentral.com/1471-230X/1/5
PAGE gels. Gels were transferred to nitrocellulose mem-
branes (Sigma) and blocked with 5% milk powder in PBS
at 4°C (overnight). These membranes were washed twice
for 10 min with wash buffer (0.1% milk powder in PBS).
Primary rat anti-mouse MadCAM-1 mAb (MECA 367,
Pharmingen, San Diego, CA) [2] was added at a concen-
tration of 10 µg/ml and incubated at room temperature
for 2 h. These membranes were washed twice with wash
buffer. Secondary goat anti-rat horseradish peroxidase
conjugated secondary antibody (Sigma) was added at a 1:
2000 dilution for 2 h. Lastly, membranes were washed 3
times and developed using the enhanced chemilumines-
cence (ECL) detection system (Amersham, La Jolla, CA).
The density of MAdCAM-1 staining was measured by
scanning the 60 kD band, using a HP ScanJet™ flatbed
scanner. Images were analyzed for density using Image
Pro Plus™ image analysis software (Media Cybernetics).
The data are expressed as a percentage of TNF-α -in-
duced level of density. Significant changes in MAdCAM-
1 densities were determined using the Instat™ statistical
package (Graphpad Software). For NF-κ B p65 blotting,
rabbit anti-p65 polyclonal (Rockland, Germany) and
goat anti-rabbit horseradish peroxidase conjugated anti-
body (Sigma) were used as primary and secondary anti-
body respectively at a 1:1000 dilution. For giving
experiment, each treatment was performed at least in
triplicate.
p65 immunoblotting
For NF-κ B p65 blotting, SVEC were pretreated for 1 h
with or without inhibitors, and then incubated for 1 h
with either vehicle or TNF-α  (20 ng/ml). Nuclear ex-
tracts were prepared as described previously [3]. rabbit
anti-p65 polyclonal (Rockland, Germany) and goat anti-
rabbit horseradish peroxidase conjugated antibody (Sig-
ma) were used as primary and secondary antibody re-
spectively at a 1:1000 dilution. For giving experiment,
each treatment was performed at least in triplicate.
TK-1 lymphocyte adhesion assay
Lymphocyte adhesion assays were performed as previ-
ously described [4] with modifications. Briefly, TK-1 cells
were suspended in Hank's Balanced salt solution (HBSS)
and radiolabeled by incubating TK-1 cells at 2 ×  107 cells/
ml with 30 µCi Na51CrO4/ml (New England Nuclear,
Natick, MA) at 37°C for 60 min. The cells were then
washed twice with ice-cold HBSS, spun at 250 g for 8
min to remove unincorporated radioactivity and resus-
pended in HBSS. The TK-1 lymphocyte cell line used in
this assay expresses high levels of the alpha 4 beta 7 in-
tegrin, which can interact with multiple ligands includ-
ing mucosal addressin-1 (MAdCAM-1), as well as VCAM-
1, L-selectin and fibronectin [5]. To activate endotheli-
um, the monolayers were incubated with TNF-α  (20 ng/
ml) for 24 h as described. Cytokine-treated endothelial
cells were washed three times with media. Labeled TK-1
cells were then added to the endothelium at a 5:1 lym-
phocyte: endothelial cell ratio [6] and allowed to bind for
30 min under static conditions. At the end of the incuba-
tion period, the supernatant was removed and the mon-
olayers were washed twice with HBSS. The remaining
endothelial cells and adherent TK-1 cells were solubilized
with IN NaOH. The 51Cr activity of the supernatant,
washed fluid, and lysate were assessed in a gamma coun-
ter. The percent of added TK-1 cells that adhered to the
SVEC monolayers was quantified as follows: %adhesion
= [cpm in lysate /(cpm in lysate + cpm in supernatant
and wash)] ×  100. the average of four identically treated
monolayers.
Statistical Analysis
All values are expressed as mean ± SE. Data were ana-
lyzed using one-way ANOVA with Bonferroni's correc-
tion for multiple comparisons. Significance was accepted
at p < 0.05.
Results
Effect of NO on MAdCAM-1 in SVEC
We investigated the effect of DETA-NONOate on TNF-α -
induced MAdCAM-1 message in SVEC by RT-PCR. Fig-
ure 1 shows the PCR products obtained with the prom-
ers, which amplify the first and second IgG-like domain
of MAdCAM-1 [7]. A strong band is detected as MAd-
CAM-1 transcript after stimulated with TNF-α  (20 ng/
ml) for 12 h. Pretreatment of DETA-NONOate (100 µM)
blocked the TNF-α  (20 ng/ml, 12 h) induced MAdCAM-
1 transcript (37.3% of TNF-α  treated) while there was no
equivalent change in GAPDH (Figure 1).
TNF-α  induces MAdCAM-1 protein expression which is re-
duced by NO donors
TNF-α  (20 ng/ml) induced MAdCAM-1 expression is
blocked both by the short-acting and long-acting NO do-
nors, SperNO and DETA-NO respectively. SperNO sig-
nificantly reduces MAdCAM-1 expression at 100 and
1000 uM (Fig. 2), while the long acting NO donor DETA-
NO significantly reduced MAdCAM-1 at a only 1/10 the
concentration of SperNO needed to reduce MAdCAM-1
expression (10 uM and 100 uM significantly attenuated
MAdCAM-1 expresssion).
NO donors block TNF-α  induces nuclear translocation of 
p65
Figure 2C shows that TNF-α  (20 ng/ml) significantly in-
creased nuclear translocation of p65, a subunit of the
p50/p65 NF-kB complex. In the presence of DETA-NO
(100 uM) or SperNO (100 uM), p65 nuclear transloca-
tion was significantly blocked as visualized by its appear-
ance in western blotting of nuclear samples.BMC Gastroenterology (2001) 1:5 http://www.biomedcentral.com/1471-230X/1/5
NO synthase inhibitors do not induce or enhance TNF-α  
induced MAdCAM-1 expression
TNF-α  induced MAdCAM-1 was not affected by either a
non-selective NO synthase inhibitor, L-NAME (1 mM) or
by a relatively selective iNOS inhibitor, 1400-ω  (100 µM)
(Fig. 3).
Adhesion of a4b7 expressing lymphocytes to MAdCAM-1 
expressing cells
Having established a role of NO donors in the regulation
of MAdCAM-1 expression by endothelial cells, we exam-
ined effects of NO donors on the adhesion of a4b7 ex-
pressing mouse lymphocyte cell line TK-1 to TNF-α -
treated endothelial cultures. Figure 4 showed that con-
trol adhesion of TK-1 cells was 12.3 ± 0.98%; TNF-α  in-
duced maximal adhesion (29.8 ± 1.30%, p < 0.001 vs.
untreated control) at 24 h. This relatively high level of
adhesion was inhibited by pre-incubation of endothelial
monolayers with anti-MAdCAM-1 antibody. MAdCAM-1
antibody reduced TK-1 adhesion to 17.0 ± 1.18% (p <
0.001 vs. TNF-α  treatment), showing that most of the
TNF-α  induced lymphocyte adhesion in this model was
MAdCAM-1 dependent. Similarly, treatment of endothe-
lial monolayers with DETA-NONOate significantly re-
duced adhesion to 19.6 ± 0.72% of that induced by TNF-
α  alone (p < 0.001). DETA-NONOate did not affect lym-
phocyte adhesion to untreated endothelial monolayers
(data not shown).
Discussion
Human IBD is characterized by the extravasation of leu-
kocytes, especially lymphocytes, into the gut, where
these cells induce and sustain chronic intestinal inflam-
mation. [8]. Lymphocyte homing to both normal tissues,
and to sites of inflammation is, regulated in part, by dif-
ferential expression of cell surface homing receptors, and
their bonds with tissue specific vascular addressins that
are sites of lymphocyte recruitment from blood [9,10,11].
Lymphocyte homing to mucosal lymphoid tissues such
as Peyer's patches, and the intestinal lamina propria in-
volves a single-chain 60-Kd adhesion glycoprotein, the
mucosal vascular addressin MAdCAM-1 [12,13].
MAdCAM-1 is expressed on endothelial cells in me-
senteric lymph nodes, lamina propria of the small and
large intestine, and the lactating mammary gland. In-
creased expression of MAdCAM-1 on murine endothelial
cells can be induced after stimulation with IL-1 and TNF-
α . [13]. MAdCAM-1 has also been detected at high levels
on colonic lamina propria venules from mice with hapten
induced colitis [14], mice injected with TNF-α  [15], or
colitic IL-2 knockout mice [16]. The interaction of the
Figure 1
RT-PCR analysis of MAdCAM-1 and GAPDH in SVEC exposed to TNF-α  with or without DETA-NONOate. In controls, only
a faint MAdCAM-1 transcript is detected (474 bp). MAdCAM-1 band is easily detected after TNF-α  stimulation (20 ng/ml).
DETA-NONOate (100 µM) blocked TNF-α -induced MAdCAM-1 transcript. In each panel, 307 bp bands indicate GAPDH
transcripts, used to evaluate amount and quality of RNA. Similar results were obtained in 3 separate experiments.BMC Gastroenterology (2001) 1:5 http://www.biomedcentral.com/1471-230X/1/5
Figure 2
Effect of NO on MAdCAM-1 in SVEC. Cells were pretreated with (A) DETA-NONOate or (B) Spermine-NONOate (SNO)
with indicated concentrations and then exposed to TNF-α  (20 ng/ml) stimulation in the continued presence of NO donors.
MAdCAM-1 expression is significantly increased after TNF-α . DETA-NONOate or Spermine-NONOate (SNO) blocked the
TNF-α  induced MAdCAM-1 expression dose dependently. Values represent mean ± SE; each group (n = 3). * p < 0.001 vs.
untreated controls, # p < 0.001 vs. TNF-α  treatment. (C) Effect of NO on p65 NF-κ B translocation. Immunoblots of NF-κ B
p65 in nuclear extracts from SVEC. Nuclear extracts (40 µg) were loaded in each well. (B) Inhibition of TNF-α  activation of
NF-κ B in SVEC. After 1 h of TNF-α  (20 ng/ml) treatment nuclear p65 of NF-κ B is induced. Pretreatment of the cells with
DETA-NONOate (100 µM) or Spermine-NONOate (100 µM) reduced the TNF-α  induced nuclear translocation of the NF-κ B
p65 subunit.BMC Gastroenterology (2001) 1:5 http://www.biomedcentral.com/1471-230X/1/5
α 4β 7 integrin on a subset of T cells, with its ligand, MAd-
CAM-1, on high venular and lymphoid endothelial cells
has been shown to be support the entry of of these lym-
phocytes into the gut in IBD [8]. However, this process is
still not well understood.
Immune-models of colitis in mice show that the MAd-
CAM-1/B7 integrin bond is essential to produce colitis.
CD45RBhigh CD4+ T lymphocytes (which normally
home to, and populate the colons of severe-combined
immune deficient ('SCID') mice) will not enter the gut af-
ter treatment of recipient animals with either MAdCAM-
1, or α 4β 7 specific antibody. This shows that this pair of
molecules is clearly involved in cell traffic into the in-
flamed gut [17]. Therefore, it is possible that there may
be unregulated MAdCAM-1 expression in IBD, and likely
that the control of MAdCAM-1 expression may be an ef-
fective potential treatment for IBD.
With respect to adhesion, adhesion of polymorphonu-
clear leukocytes has been shown to be enhanced by treat-
ment with NOS inhibitors, similarly Hokari et al. [18]
have also demonstrated that L-NAME promotes the ad-
hesion of T-lymphocytes cells to endothelium in vivo.
NO is an important modulator of adhesion molecule ex-
pression in both acute and chronic inflammatory states,
and may influence the course of IBD. It is known that NO
can function both as an oxidant, or antioxidant depend-
ing on the availability of reactive oxygen species [19].
Similarly, the concentration of NO can also augment
[20,21] or inhibit [22,23] oxygen-radical mediated tissue
damage and lipid peroxidation. It has also been reported
that inhibition of endothelial nitric oxide synthases (us-
ing the non-selective NOS inhibitor L-NAME), induces
endothelial adhesion molecules (ICAM-1 and VCAM-1)
in HUVEC [24,25].
With respect to NO in inflammatory bowel disease. Sing-
er et al., [26] found that iNOS expression was significant-
ly increased in colonic epithelia from individuals with
IBD. In iNOS deficient mice, McCafferty et al. (1997) [27]
reported that acetic acid-induced colitis was more severe
in iNOS-/- deficient animals, consistent with a protective
role of iNOS derived NO in colitis.
De Caterina et al. [28] reported that in another model,
NO blocked the TNF-α  or IL-1β  induced expression of
VCAM-1, E-selectin, and ICAM-1. Similarly, GSNO also
reduced NF-kB activation (as measured by EMSA). Fur-
ther, Binion et al. [29] reported that iNOS expression in
human intestinal micro vascular endothelial cells inhib-
ited leukocyte adhesion, indicating that iNOS derived
NO may control inflammation in human IBD. Further
support of this hypothesis comes from a more recent re-
port by Binion's group showing that individuals afflicted
with Crohn's colitis have an apparent inability to express
iNOS in their intestinal microvascular endothelium [29].
McCafferty et al., [27,30] suggest that in IBD, iNOS
blocks an early, obligatory phase of inflammation, but
perhaps not the chronic phase. Kubes and McCafferty
[31] suggest in IBD, NO may be either beneficial or detri-
mental and may reflect the tissue source (cell type), en-
zymatic source of NO (eNOS vs. iNOS) and rate of NO
production, as well as the bioavailability of oxidants in
these different models.
In this present study, we investigated how MAdCAM-1
expression in cultured endothelial cells is altered by NO
donors and by NO synthase inhibitors. We have also ex-
amined how cytokines and NO-modifying agents control
Figure 3
Effect of NOS inhibitors on MAdCAM-1 in SVEC. Cells were pretreated with vehicle, L-NAME or 1400ω  with indicated con-
centrations and then exposed to TNF-α  (20 ng/ml) stimulation in the continued presence of the NOS inhibitor. NOS inhibitors
themselves did not induce MAdCAM-1 expression nor did they increase MAdCAM-1 in TNF-α  treated cells. Similar results
were obtained in 3 separate experiments.BMC Gastroenterology (2001) 1:5 http://www.biomedcentral.com/1471-230X/1/5
adhesion of α 4β 7-expressing mouse lymphocytes in re-
sponse to TNF-α .
We observed that both a short and long-acting NO donor
significantly reduce TNF-α -induced expression of MAd-
CAM-1 expression in lymphatic endothelial cells. The ef-
fects of NO donors appear to reflect their ability to
prevent the nuclear translocation of NF-kB. The MAd-
CAM-1 promoter has several NF-kB binding sites [32],
and are necessary to induce MAdCAM-1 expression.
Both a short and long acting NO donor blocked MAd-
CAM-1 induction, but the slow-releasing NO DETA-NO
was apparently at least 10 times more effective than
SperNO (on a molar basis). This probably reflects the
need for persistently elevated NO to block cytokine sign-
aling in this system.
In this model, the mechanism through which NO donors
limit inflammation is by NF-kB inhibition, since these
NO donors effectively block p65 translocation into the
nucleus. Khan et al. [33] demonstrated that NO donors
blocked TNF-α  induced NF-κ B activation in human um-
bilical vein endothelial cells as measured by EMSA. Sim-
ilarly, Spiecker [34] showed that GSNO, blocked TNF-α
induced NF-κ B activation by EMSA in human saphenous
vein endothelium. However in that model Iκ Bα , the in-
hibitor of the NF-kB complex was still degraded. There-
fore, NO might limit NF-kB activation through pathways
independent of IkB-a. In that report, NO was found to in-
Figure 4
Adhesion of TK-1 cells on SVEC. TNF-α  induced significant increase of TK-1 cells adhesion. This increased adhesion was signif-
icantly inhibited by pretreatment with MAdCAM-1 Ab. Pretreatment of DETA-NONOate (100 µM) also significantly inhibited
TNF-α  (20 ng/ml, 24 h) -induced TK-1 adhesion on SVEC. Each value represents the mean ± SE; each group (n = 4). * p <
0.001, ** p < 0.05 vs. untreated control, # p < 0.001 vs. TNF-α  treatment.BMC Gastroenterology (2001) 1:5 http://www.biomedcentral.com/1471-230X/1/5
duce Iκ B synthesis through activation of its promoter,
therefore, increased IkB-a might also contribute to NF-
kB inhibition . Several other possible pathways, e.g. p38,
p42/44 MAPK and transcription factors, e.g. SP1 and
possibly AP2, Adh1 (ETF), PEA3 sites [32] which could
also contribute to NF-kB dependent gene activation and
might participate in NO mediated MAdCAM-1 regula-
tion by cytokines. [35] have reported that an NO-releas-
ing derivative of mesalamine, (one agent currently used
to treat gut inflammation), exhibits enhanced anti-in-
flammatory effects compared to the parent compound.
While NO donors are not currently used for treatment of
IBD, the literature and our data here suggest that NO do-
nors could be beneficial.
An improved understanding of the interactions of these
signals may improve our ability to understand the role of
MAdCAM-1 in IBD and design effective therapies to treat
it.
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